• PolyPeptide Group revenue rose 41.6% to EUR 236.6 million in H1 2026.
• EBITDA margin widened 18 percentage points to 20.7%; result for the period returned to profit at about EUR 9 million.
• Metabolic therapeutics revenue climbed to EUR 161.7 million, about 68% of total revenue; large pharma customers accounted for about 72%.
• Guidance raised to 25%-30% revenue growth in 2026, with a high-teens EBITDA margin and capital expenditures at 15%-20% of revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2367908_en) on July 20, 2026, and is solely responsible for the information contained therein.